What is mass spectrometry and how does it complement LC?

Mass spectrometry (MS) identifies molecules by measuring their mass-to-charge ratio after ionizing them — creating a unique fingerprint for each compound. Combined with liquid chromatography (LC-MS), it enables detection and quantification of complex molecules at very low concentrations, making it essential for drug metabolism studies, biomarker discovery, proteomics, and food contamination testing. The combination of Agilent's LC and MS instruments serves the high-value life science research and pharmaceutical market.

What are CDMO and CRO services and why does Thermo Fisher provide them?

CDMOs (Contract Development and Manufacturing Organizations) manufacture drugs for pharmaceutical companies that outsource production — Thermo Fisher's pharma services segment (including the former Patheon acquisition) manufactures clinical and commercial drug products for clients. CROs (Contract Research Organizations) conduct clinical trials and research services on behalf of pharma companies — Thermo Fisher's PPD business provides these services. Together, they provide fee-for-service pharma outsourcing revenue less cyclical than instrument hardware sales.

What is the China risk for life science tool companies like Agilent and Thermo Fisher?

China represents 10-20% of revenue for major life science tool companies. Risks include: (1) economic slowdown reducing lab spending budgets; (2) government policies encouraging 'buy Chinese' — favoring domestic instrument makers over Agilent, Waters, or Thermo Fisher; (3) U.S.-China geopolitical tensions restricting technology sales; and (4) currency (RMB/USD) translation effects on reported revenues. Chinese domestic life science tool companies have been developing instruments to replace imported products, a long-term competitive pressure for multinational suppliers.

Data as of: June 16, 2026

brimindinvest.com / compare / tmo-vs-agilentLIVE

TMO

Thermo Fisher Scientific Inc. · Healthcare - Life Science Tools & Services

N/A

N/A this month

VERSUS

COMPARE

A

Agilent Technologies, Inc. · Healthcare - Analytical Instruments

N/A

N/A this month

Comparison scoreboard

MIXED SETUP

AI Scorei

TMO N/A

A N/A

1Y Returni

TMO N/A

A N/A

Fwd P/Ei

TMO N/A

A N/A

Target Up.i

TMO N/A

A N/A

Op. Margini

TMO N/A

A N/A

Quick take

TMO vs A Stock Comparison: AI Score, Valuation, Performance and Upside

ShareX LinkedIn Reddit Facebook WhatsApp

TMO (Thermo Fisher Scientific) is the global life science tools leader with unmatched breadth across instruments, reagents, and pharma services, while A (Agilent Technologies) is a focused analytical instruments specialist with leadership in chromatography, mass spectrometry, and genomics. Thermo Fisher is larger and more diversified; Agilent is more focused on analytical chemistry and materials characterization.

TMO vs A is life science tools scale leader (Thermo Fisher's end-to-end laboratory and pharma services platform) versus focused analytical instruments specialist (Agilent's LC/MS, genomics, and pathology for pharma, food, and environmental) — both essential life science tool suppliers with pharma spending exposure.

Normalized 1Y performance

TMO

A

Not enough data to chart yet.

Recent returns

TMO

A

Not enough data to chart yet.

Analyst price targets & sentiment

Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.

TMO

Price target data unavailable

N/A

A

Price target data unavailable

N/A

Who should consider this stock?

TMO may suit investors who:

Want the world's largest life science tools company with unparalleled product breadth, pharma services revenue through CDMO/CRO capabilities, and a long track record of value-creating acquisitions
Value Thermo Fisher's bioprocessing recovery as a catalyst for growth re-acceleration following the COVID normalization and biopharma inventory destocking cycle
Prefer maximum life science diversification across instruments, reagents, consumables, diagnostics, and pharma services from a single high-quality compounder

A may suit investors who:

Want focused analytical instruments exposure through Agilent's leadership in liquid chromatography, mass spectrometry, and genomics serving pharmaceutical, food, and environmental markets
Value Agilent's end market diversification (food safety, environmental testing, forensics) as a buffer against purely pharma-driven spending cycles
See Agilent's DAKO oncology pathology business as growing companion diagnostic and cancer biomarker testing revenues tied to personalized medicine adoption

Performance & AI score

Performance & AI score
Metric	TMO	A
AI scorei	N/A	N/A
AI ranki	N/A	N/A
Latest closei	N/A	N/A
1M returni	N/A	N/A
6M returni	N/A	N/A
1Y returni	N/A	N/A

Valuation & upside potential

Valuation & upside potential
Metric	TMO	A
Market capi	N/A	N/A
Trailing P/Ei	N/A	N/A
Forward P/Ei	N/A	N/A
Price/Salesi	N/A	N/A
EV/Revenuei	N/A	N/A
Analyst targeti	N/A	N/A
Target upsidei	N/A	N/A

Growth, profitability & risk

Growth, profitability & risk
Metric	TMO	A
Revenue growthi	N/A	N/A
Earnings growthi	N/A	N/A
EPS growthi	N/A	N/A
FCF margini	N/A	N/A
Operating margini	N/A	N/A
Profit margini	N/A	N/A
ROIC proxyi	N/A	N/A
Return on equityi	N/A	N/A
Dividend yieldi	N/A	N/A
Payout ratioi	N/A	N/A
Dividend growth streaki	N/A	N/A
Betai	N/A	N/A
Debt/equityi	N/A	N/A
Current ratioi	N/A	N/A
Quick ratioi	N/A	N/A

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

TMO max drawdowniN/A

A max drawdowniN/A

TMO max wkly dropiN/A

A max wkly dropiN/A

5Y risk snapshot

TMO max drawdowniN/A

A max drawdowniN/A

TMO max wkly dropiN/A

A max wkly dropiN/A

10Y risk snapshot

TMO max drawdowniN/A

A max drawdowniN/A

TMO max wkly dropiN/A

A max wkly dropiN/A

Performance metrics by period

Performance metrics by period
Period	Metric	TMO	A
1Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A
5Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A
10Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A

AI Prediction Signali

Members only

Next 5 trading days

TMO

+2.8%BUY

+1.1%HOLD

Next 30 trading days

TMO

+6.4%BUY

+3.2%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Business comparison

Business comparison
Category	TMO	A
Company	Thermo Fisher Scientific Inc.	Agilent Technologies, Inc.
Sector	Healthcare - Life Science Tools & Services	Healthcare - Analytical Instruments
Industry	N/A	N/A
Core business	Thermo Fisher Scientific is the world's largest life science tools company, providing laboratory instruments, reagents, consumables, and CRO/CMO services for pharmaceutical and biotech drug development, research, clinical diagnostics, and environmental testing — operating as the essential supplier to life science research globally.	Agilent Technologies provides analytical instruments, consumables, software, and services for life science and applied markets — including liquid chromatography (LC), mass spectrometry (MS), gas chromatography (GC), spectroscopy, pathology (DAKO cancer diagnostics), and genomics (SureSelect) for pharma, food safety, environmental, and forensics customers.
Investor focus	Investors track Thermo Fisher's organic revenue growth (ex-COVID testing and vaccines), bioprocessing recovery, Life Science Solutions segment performance, pharma services (CDMO/CRO) bookings, and the company's capital allocation between acquisitions and buybacks.	Investors track Agilent's revenue by end market (pharma, food, environmental, forensics), instrument order trends, liquid chromatography and mass spectrometry market share, and margin efficiency.

TMO strengths

Scale leadership as the world's largest life science tools company creates unique breadth advantage — researchers can source most laboratory needs from a single Thermo Fisher supplier relationship
Diversified across four segments (Life Science Solutions, Analytical Instruments, Laboratory Products & Services, Pharma Services) provides resilience when any single end market slows
Pharma services (PPD CRO, CDMO manufacturing) provides a fee-for-service recurring revenue stream less dependent on instrument purchase cycles

A strengths

Market-leading position in liquid chromatography (LC) and LC/MS instruments used extensively in pharmaceutical quality control and new drug development
Diversified end markets spanning pharma, food safety, environmental testing, and forensics provides resilience when any single end market slows — food and environmental testing are less correlated to pharma spending cycles
DAKO oncology pathology products provide diagnostics exposure to companion diagnostics and cancer biomarker testing as personalized medicine grows

Risks to watch — TMO

Biopharma funding environment affects instrument purchasing — when biotech funding is tight, smaller biotech companies reduce capital equipment purchases, affecting Thermo Fisher's instrument revenue
Post-COVID normalization created a significant air pocket in revenue — COVID testing, vaccine manufacturing, and pandemic-related demand was extraordinary and has since normalized sharply
Thermo Fisher's scale means acquisitions must be increasingly large to move the needle — smaller bolt-on acquisitions have less relative impact than on smaller peers

Risks to watch — A

Pharmaceutical market exposure means Agilent shares the same biopharma spending cycle risks as other life science tool companies — funding tightness affects instrument purchases
Competition from Waters Corporation in LC/MS and Bruker in mass spectrometry means Agilent must continuously invest in instrument performance to maintain market share
China represents a significant portion of Agilent revenue — geopolitical tensions, economic slowdown, and Chinese government buy-domestic preferences create headwinds for multinational lab instrument suppliers

Frequently asked questions

Liquid chromatography (LC) is an analytical technique that separates, identifies, and quantifies compounds in a liquid mixture by flowing them through a stationary phase material at high pressure (HPLC — High Performance Liquid Chromatography). In pharmaceuticals, LC is the primary method for quality control testing of drug purity, concentration, and impurity profiling — required by FDA and global regulators for every drug batch. This non-discretionary regulatory requirement makes LC instrument consumables and service highly recurring.

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides

Related comparisons